Table 1.
Clinical characteristics of non-small cell lung cancer patients with brain metastases treated with brain RT stratified by EGFR mutation status
|
Characteristics |
Total(N = 43) |
EGFR mutation status |
P |
|
|---|---|---|---|---|
| Positive(n = 30) | Negative(n = 13) | |||
| Age, years |
|
|
|
0.332 |
| Median (range) |
59 (35-83) |
|
|
|
| <60 |
22 (51) |
17 (57) |
5 (38) |
|
| ≧60 |
21 (49) |
13 (43) |
8 (62) |
|
| Gender |
|
|
|
0.054 |
| Female |
20 (47) |
17 (57) |
3 (23) |
|
| Male |
23 (53) |
13 (43) |
10 (77) |
|
| Smoking history |
|
|
|
0.043 |
| Never |
27 (63) |
22 (73) |
5 (38) |
|
| Ever |
16 (37) |
8 (27) |
8 (62) |
|
| ECOG performance status |
1.60±0.88 |
1.60±0.89 |
1.62±0.87 |
0.959 |
| RPA class |
|
|
|
1.000 |
| Class I |
5 (12) |
4 (13) |
1 (8) |
|
| Class II |
31 (72) |
21 (70) |
10 (77) |
|
| Class III |
7 (16) |
5 (17) |
2 (15) |
|
| Primary tumor status |
|
|
|
1.000 |
| Controlled |
29 (67) |
20 (67) |
9 (69) |
|
| Uncontrolled |
14 (33) |
10 (33) |
4 (31) |
|
| Extracranial metastases |
|
|
|
1.000 |
| Absent |
12 (28) |
8 (27) |
4 (31) |
|
| Present |
31 (72) |
22 (73) |
9 (69) |
|
| Number of BM |
|
|
|
0.491 |
| ≦3 |
14 (33) |
11 (37) |
3 (23) |
|
| >3 |
29 (67) |
19 (63) |
10 (77) |
|
| Size of largest BM (mm) |
22.07±10.91 |
24.51±11.74 |
16.45±5.89 |
0.024 |
| Hemorrhagic BM |
|
|
|
0.019 |
| No |
32 (74) |
19 (63) |
13 (100) |
|
| Yes |
11 (26) |
11 (37) |
0 (0) |
|
| Total dose |
|
|
|
0.310 |
| ≦40 Gy2 |
26 (60) |
20 (67) |
6 (46) |
|
| >40 Gy2 |
17 (40) |
10 (33) |
7 (54) |
|
| EGFR TKI during RT |
|
|
|
0.324 |
| No |
24 (56) |
15 (50) |
9 (69) |
|
| Yes |
19 (44) |
15 (50) |
4 (31) |
|
| Type of EGFR TKI |
|
|
|
1.000 |
| Gefitinib |
5 (26) |
4 (27) |
1 (25) |
|
| Erlotinib |
14 (74) |
11 (73) |
3 (75) |
|
| Chemotherapy during RT |
|
|
|
1.000 |
| No |
33 (77) |
23 (77) |
10 (77) |
|
| Yes | 10 (23) | 7 (23) | 3 (23) | |
Abbreviations: ECOG Eastern Cooperative Oncology Group, RPA recursive partitioning analysis, BM brain metastases, Gy2 biologically equivalent dose equal to fraction size of 2 Gy, TKI tyrosine kinase inhibitor.
Categorical data were presented as number (percentage) and continuous data were presented as mean ± standard deviation.